Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC-Pf7, a Pox-Vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium falciparum Malaria

Verfasser / Beitragende:
[Christian F. Ockenhouse, Pei-fang Sun, David E. Lanar, Bruce T. Wellde, B. Ted Hall, Kent Kester, Jose A. Stoute, Alan Magill, Urszula Krzych, Linda Farley, Robert A. Wirtz, Jerald C. Sadoff, David C. Kaslow, Sanjai Kumar, L. W. Preston Church, James M. Crutcher, Benjamin Wizel, Stephen Hoffman, Ajit Lalvani, Adrian V. S. Hill, John A. Tine, Kenneth P. Guito, Charles de Taisne, Robin Anders, Toshihiro Horii, Enzo Paoletti, W. Ripley Ballou]
Ort, Verlag, Jahr:
1998
Enthalten in:
Journal of Infectious Diseases, 177/6(1998-06), 1664-1673
Format:
Artikel (online)
ID: 398247307